

David A Fraser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1223943/publications.pdf>

Version: 2024-02-01

9
papers

130
citations

1477746
6
h-index

1588620
8
g-index

9
all docs

9
docs citations

9
times ranked

250
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1095-1097.	4.3	53
2	Polymorphisms in an interferon- γ receptor-1 gene marker and susceptibility to periodontitis*. <i>Acta Odontologica Scandinavica</i> , 2003, 61, 297-302.	0.9	19
3	Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. <i>Hepatology Communications</i> , 2020, 4, 193-207.	2.0	15
4	A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. <i>Journal of Hepatology</i> , 2022, 76, 800-811.	1.8	15
5	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. <i>Liver International</i> , 2020, 40, 2860-2876.	1.9	12
6	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. <i>Cardiology</i> , 2016, 135, 3-12.	0.6	11
7	SAT-346-Icosabutate induces a potent reduction in hepatic oxidative stress in rodent models of metabolic stress and fibrosing NASH. <i>Journal of Hepatology</i> , 2019, 70, e791.	1.8	2
8	Structurally engineered fatty acid 1024 (<sc>SEFA</sc> -1024) improves diet-induced obesity, insulin resistance, and fatty liver disease. <i>Lipids</i> , 0, , .	0.7	2
9	LBP-10-A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH. <i>Journal of Hepatology</i> , 2019, 70, e145-e146.	1.8	1